title: Development of peptidomimetic ligands of Pro-Leu-Gly-NH(2) as allosteric modulators of the dopamine D(2) receptor.
abstract: A variety of stable, small-molecule peptidomimetic ligands have been developed to elucidate the mechanism by which the neuropeptide Pro-Leu-Gly-NH(2) (PLG) modulates dopaminergic neurotransmission. Photoaffinity labeling ligands based upon PLG peptidomimetics have been used to establish that PLG binds to the D(2) dopamine receptor at a site that is different from the orthosteric site, thus making PLG and its peptidomimetics allosteric modulators of the dopamine receptor. Through the design, synthesis and pharmacological evaluation of conformationally constrained peptidomimetics containing lactam, bicyclic, and spiro-bicyclic scaffolds, support was provided for the hypothesis that the bioactive conformation of PLG is a type II β-turn. In addition, studies with peptidomimetics designed to mimic either a type VI β-turn or polyproline II helix conformation yielded molecules that were able to modulate dopamine receptors because of their ability to place the carboxamide NH(2) pharmacophore in the same topological space as that seen in the type II β-turn. Extensive studies with the spiro-bicyclic PLG peptidomimetics also established that both positive and negative modes of modulation were possible for the same series of peptidomimetics simply as a result of minor differences in the stereochemistry about the bridgehead carbon within the scaffold. This information was used to transform existing positive modulators into negative modulators, which demonstrated that small structural changes in the spiro-bicyclic dopamine receptor modulators are capable of causing major changes in the modulatory activity of PLG peptidomimetics.
authors: Department of Medicinal Chemistry, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA.
authors: Swapna
authors: S
authors: Bhagwanth
authors: Ram K
authors: RK
authors: Mishra
authors: Rodney L
authors: RL
authors: Johnson
keywords: Pro-Leu-Gly-NH; allosteric modulation; dopamine D receptor; peptidomimetic; spiro-bicyclic scaffold
references: J Med Chem. 2007 Dec 27;50(26):6725-9
references: 18052024
references: J Med Chem. 1986 Oct;29(10):2104-7
references: 2876104
references: Dis Nerv Syst. 1977 Apr;38(4):303-7
references: 14814
references: J Med Chem. 2006 Jan 12;49(1):307-17
references: 16392815
references: Trends Pharmacol Sci. 2003 Apr;24(4):172-7
references: 12707003
references: Recept Channels. 2002;8(5-6):261-8
references: 12690954
references: Peptides. 1998;19(2):403-6
references: 9493876
references: ACS Chem Neurosci. 2012 Apr 18;3(4):274-84
references: 22860194
references: J Med Chem. 1993 Jan 22;36(2):256-63
references: 8093736
references: J Med Chem. 2004 Dec 16;47(26):6595-602
references: 15588094
references: Eur J Pharmacol. 2010 Sep 1;641(2-3):96-101
references: 20639138
references: Bioorg Med Chem Lett. 1998 Nov 17;8(22):3137-42
references: 9873691
references: J Med Chem. 1993 Oct 29;36(22):3481-3
references: 7901418
references: J Med Chem. 2009 Apr 9;52(7):2043-51
references: 19271750
references: J Med Chem. 2003 Feb 27;46(5):727-33
references: 12593653
references: Annu Rev Pharmacol Toxicol. 1993;33:281-307
references: 8494342
references: Peptides. 2007 Oct;28(10):2009-15
references: 17766011
references: Peptides. 2003 Feb;24(2):313-9
references: 12668218
references: Org Lett. 2006 Mar 2;8(5):983-6
references: 16494490
references: Int J Pept Protein Res. 1980 Nov;16(5):464-70
references: 7216621
references: Methods Find Exp Clin Pharmacol. 1983;5(4):203-33
references: 6136640
references: Org Lett. 2005 Jan 6;7(1):35-8
references: 15624971
references: Med Res Rev. 2010 May;30(3):463-549
references: 19557759
references: Bioorg Med Chem Lett. 1999 Aug 16;9(16):2349-52
references: 10476867
references: J Med Chem. 1993 Aug 6;36(16):2356-61
references: 8103113
references: J Am Chem Soc. 2003 Dec 31;125(52):16243-60
references: 14692766
references: Life Sci I. 1971 Nov 15;10(22):1279-83
references: 4947365
references: Science. 1981 Dec 11;214(4526):1261-2
references: 6117947
references: J Med Chem. 1986 Oct;29(10):2100-4
references: 2876103
references: Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(5):821-7
references: 1981396
references: J Med Chem. 1979 Aug;22(8):931-5
references: 40028
references: J Med Chem. 2012 Feb 23;55(4):1445-64
references: 22148748
references: J Med Chem. 1990 Jul;33(7):1848-51
references: 1694545
references: J Am Chem Soc. 1973 Oct 31;95(22):7523-4
references: 4747887
references: J Med Chem. 1999 Feb 25;42(4):628-37
references: 10052970
references: Org Biomol Chem. 2008 May 7;6(9):1647-54
references: 18421399
references: J Med Chem. 1999 Apr 22;42(8):1441-7
references: 10212130
references: J Med Chem. 1988 Jul;31(7):1430-6
references: 3385734
references: Peptides. 1997;18(8):1209-15
references: 9396063
references: Schizophr Res. 2011 Jan;125(1):88-92
references: 21036015
references: J Org Chem. 2000 Nov 3;65(22):7406-16
references: 11076597
references: J Pharmacol Exp Ther. 2005 Dec;315(3):1228-36
references: 16126839
references: J Neurochem. 1988 Mar;50(3):960-8
references: 2892892
references: J Med Chem. 1991 Jun;34(6):1777-89
references: 2061921
references: Int J Pept Protein Res. 1989 Mar;33(3):181-90
references: 2565891
references: Biochem Biophys Res Commun. 1971 Jun 18;43(6):1376-81
references: 4398196
references: Int J Pept Protein Res. 1982 Feb;19(2):143-52
references: 6126459
references: J Org Chem. 1996 May 3;61(9):3138-3144
references: 11667176
references: J Med Chem. 1999 Jul 29;42(15):2977-87
references: 10425107